Exagen Inc Stock Buy Hold or Sell Recommendation
| XGN Stock | USD 3.88 0.19 5.15% |
Considering the 90-day investment horizon and your way above-average risk tolerance, our recommendation regarding Exagen Inc is 'Sell'. The recommendation algorithm takes into account all of Exagen's available fundamental, technical, and predictive indicators you will find on this site.
Check out Exagen Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Exagen and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Exagen |
Execute Exagen Buy or Sell Advice
The Exagen recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Exagen Inc. Macroaxis does not own or have any residual interests in Exagen Inc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Exagen's advice using the current market data and latest reported fundamentals.
Time Horizon
2 Years |
Risk Tolerance
I can tolerate above average risk |
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Exagen Trading Alerts and Improvement Suggestions
| Exagen Inc generated a negative expected return over the last 90 days | |
| Exagen Inc has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 55.64 M. Reported Net Loss for the year was (15.12 M) with profit before taxes, overhead, and interest of 33.11 M. | |
| Exagen Inc has about 76.39 M in cash with (13.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Exagen Inc has a poor financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company outstanding shares are owned by insiders | |
| Latest headline from Macroaxis: Are Exagen unfluctuating technical and fundamental indicators contributing to the recent decline |
Exagen Returns Distribution Density
The distribution of Exagen's historical returns is an attempt to chart the uncertainty of Exagen's future price movements. The chart of the probability distribution of Exagen daily returns describes the distribution of returns around its average expected value. We use Exagen Inc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Exagen returns is essential to provide solid investment advice for Exagen.
| Mean Return | -0.35 |
| Value At Risk | -11.56 |
| Potential Upside | 15.86 |
| Standard Deviation | 8.18 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Exagen historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Exagen Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Exagen, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Exagen Inc back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Geode Capital Management, Llc | 2024-12-31 | 98.1 K | |
| Palumbo Wealth Management Llc | 2024-12-31 | 86.7 K | |
| Ubs Group Ag | 2024-12-31 | 64.2 K | |
| Nantahala Capital Management, Llc | 2024-12-31 | 62.1 K | |
| Penbrook Management Llc | 2024-12-31 | 44.6 K | |
| Wasatch Advisors Lp | 2024-12-31 | 43 K | |
| Creative Planning Inc | 2024-12-31 | 35.5 K | |
| State Street Corp | 2024-12-31 | 33.7 K | |
| Blackrock Inc | 2024-12-31 | 33.4 K | |
| Rtw Investments, Llc | 2024-12-31 | 1.5 M | |
| Cowen And Company, Llc | 2024-09-30 | 891.4 K |
Exagen Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (14.6M) | 42.0M | (37.0M) | (25.9M) | (14.5M) | (13.7M) | |
| Free Cash Flow | (14.5M) | (22.6M) | (36.5M) | (15.3M) | (13.8M) | (14.5M) | |
| Depreciation | 546K | 948K | 1.6M | 2.2M | 1.7M | 1.0M | |
| Other Non Cash Items | 805K | 819K | 7.6M | 3.1M | 1.4M | 1.4M | |
| Capital Expenditures | 455K | 2.4M | 4.3M | 828K | 515K | 489.3K | |
| Net Income | (16.7M) | (26.9M) | (47.4M) | (23.7M) | (15.1M) | (15.9M) | |
| End Period Cash Flow | 57.5M | 99.5M | 62.6M | 36.7M | 22.2M | 36.0M | |
| Investments | (455K) | (2.4M) | (4.3M) | (1.1M) | (515K) | (540.8K) | |
| Net Borrowings | (138K) | (249K) | (525K) | (696K) | (626.4K) | (595.1K) | |
| Dividends Paid | 6.7M | 142K | 390K | 9.9M | 11.4M | 12.0M | |
| Change To Netincome | 871K | 3.1M | 5.4M | 11.9M | 13.6M | 14.3M |
Exagen Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Exagen or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Exagen's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Exagen stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 2.53 | |
σ | Overall volatility | 8.25 | |
Ir | Information ratio | -0.04 |
Exagen Volatility Alert
Exagen Inc is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Exagen's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Exagen's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Exagen Fundamentals Vs Peers
Comparing Exagen's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Exagen's direct or indirect competition across all of the common fundamentals between Exagen and the related equities. This way, we can detect undervalued stocks with similar characteristics as Exagen or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Exagen's fundamental indicators could also be used in its relative valuation, which is a method of valuing Exagen by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Exagen to competition |
| Fundamentals | Exagen | Peer Average |
| Return On Equity | -0.94 | -0.31 |
| Return On Asset | -0.17 | -0.14 |
| Profit Margin | (0.27) % | (1.27) % |
| Operating Margin | (0.25) % | (5.51) % |
| Current Valuation | 68.09 M | 16.62 B |
| Shares Outstanding | 17.9 M | 571.82 M |
| Shares Owned By Insiders | 27.64 % | 10.09 % |
| Shares Owned By Institutions | 54.26 % | 39.21 % |
| Number Of Shares Shorted | 32.45 K | 4.71 M |
| Price To Book | 7.04 X | 9.51 X |
| Price To Sales | 1.19 X | 11.42 X |
| Revenue | 55.64 M | 9.43 B |
| Gross Profit | 33.11 M | 27.38 B |
| EBITDA | (11.14 M) | 3.9 B |
| Net Income | (15.12 M) | 570.98 M |
| Cash And Equivalents | 76.39 M | 2.7 B |
| Cash Per Share | 4.70 X | 5.01 X |
| Total Debt | 3.18 M | 5.32 B |
| Debt To Equity | 0.55 % | 48.70 % |
| Current Ratio | 9.30 X | 2.16 X |
| Book Value Per Share | 0.54 X | 1.93 K |
| Cash Flow From Operations | (13.28 M) | 971.22 M |
| Short Ratio | 0.17 X | 4.00 X |
| Earnings Per Share | (0.83) X | 3.12 X |
| Target Price | 6.75 | |
| Number Of Employees | 209 | 18.84 K |
| Beta | 1.4 | -0.15 |
| Market Capitalization | 66.04 M | 19.03 B |
| Total Asset | 44.69 M | 29.47 B |
| Retained Earnings | (294.33 M) | 9.33 B |
| Working Capital | 22.95 M | 1.48 B |
| Net Asset | 44.69 M |
Note: Acquisition by Tullis James L L of 9000 shares of Exagen at 16.41 subject to Rule 16b-3 [view details]
Exagen Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Exagen . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Exagen Buy or Sell Advice
When is the right time to buy or sell Exagen Inc? Buying financial instruments such as Exagen Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Exagen in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Trump Equities Thematic Idea Now
Trump Equities
Stocks that have significantly increased in valuation since Trump was elected president of the United States. The Trump Equities theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Trump Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Exagen Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets | Return On Equity |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.